Sanofi SA (SNY)

39.18
0.13 0.33
NYSE : Health Care
Prev Close 39.05
Open 39.08
Day Low/High 38.83 / 39.24
52 Wk Low/High 37.41 / 51.88
Volume 1.31M
Avg Volume 2.31M
Exchange NYSE
Shares Outstanding 2.57B
Market Cap 101.42B
EPS 1.90
P/E Ratio 21.18
Div & Yield 1.66 (4.20%)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABT, AXLL, BOKF, FLY, KCAP, RWC Downgrades: BBRG, CCOI, DL, EMG, FLO, HWBK, IIJI, INOD, MTH, NOA, SMCI, SNY, TGNA Initiations: BUFF, GI, NSA Read on to get TheStreet Quant Ratings' detailed report:

Medivation Scores Premium in Sale to Pfizer

Medivation Scores Premium in Sale to Pfizer

Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.

Pfizer to Pick Up Medivation in All-Cash Deal

PFE is trading up on the announcement, and the deal should add to earnings in 2017.

Pfizer Is Buying Medivation for $14 Billion

Pfizer Is Buying Medivation for $14 Billion

Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.

5 Things You Must Know Before the Market Opens Monday

5 Things You Must Know Before the Market Opens Monday

Pfizer finalizes a deal to buy cancer drugmaker Medivation; ChemChina gets U.S. approval for its takeover of Syngenta; Viacom CEO Philippe Dauman is ousted.

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

What CVS and Express Scripts' Drug Exclusion Lists Means for Your Portfolio

What CVS and Express Scripts' Drug Exclusion Lists Means for Your Portfolio

Earlier this month the two major pharmacy benefit managers, CVS Caremark CVS and Express Scripts ESRX released lists of drugs they will no longer cover in 2017.

Biotech Pop-Up Party in Full Swing

Biotech Pop-Up Party in Full Swing

The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

Pokèmon Go Reflects the Increasingly Lucrative Business of Mobile Gaming

Pokèmon Go Reflects the Increasingly Lucrative Business of Mobile Gaming

The alternate reality mobile gaming app has been downloaded over 75 million times in less than a month.

Pokèmon Go Is Just the Tip of the Mobile-Gaming Iceberg

Pokèmon Go Is Just the Tip of the Mobile-Gaming Iceberg

The mobile-gaming market is expected to surpass console games this year, according to Deloitte.

5 Things You Must Know Before the Market Opens Friday

5 Things You Must Know Before the Market Opens Friday

Alphabet shares rise after the company handily beats quarterly estimates; Amazon's cloud computing business continues to shine; U.S. stock futures point lower.

European Markets Steady on Earnings and Data Deluge

European Markets Steady on Earnings and Data Deluge

GDP growth in the eurozone slowed in the second quarter.

Sanofi Quarterly Earnings, Sales Slide, but It Reiterates Discipline on Medivation

Sanofi Quarterly Earnings, Sales Slide, but It Reiterates Discipline on Medivation

Sanofi says currency headwinds will erode 4% from full-year earnings per share.

Sanofi's Chart Shows Promise

Sanofi's Chart Shows Promise

Our first upside target is the $50 to $52 area and a close below $40 would extend the base.

Sanofi (SNY) Stock Lower Ahead of Friday’s Q2 Earnings

Sanofi (SNY) Stock Lower Ahead of Friday’s Q2 Earnings

Sanofi (SNY) stock is declining on Thursday afternoon ahead of the company’s 2016 second quarter results, due out before tomorrow’s market open.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMOT, ANGI, CBT, ELY, FTAI, GNBC, LOGM, NCR, SIX, SKUL, SLAB, SNY, SONS, TRK, TRN, UFS, VRTX, WES, ZNGA Downgrades: AF, BA, TER, WEX Initiations: FSV Read on to get TheStreet Quant Ratings' detailed report:

Sanofi Receives FDA Approval Of AdlyxinTM For Treatment Of Adults With Type 2 Diabetes

Sanofi Receives FDA Approval Of AdlyxinTM For Treatment Of Adults With Type 2 Diabetes

- AdlyxinTM is approved as Lyxumia® in more than 60 countries -

Sanofi Pasteur Ships First Of Its 2016-2017 Seasonal Influenza Vaccine Doses In United States

Sanofi Pasteur Ships First Of Its 2016-2017 Seasonal Influenza Vaccine Doses In United States

- World's largest influenza vaccine manufacturer expects to distribute more than 65 million vaccine doses to help protect people six months and older against the flu -

Biogen Should Either a Buyer or a Seller Be

Biogen Should Either a Buyer or a Seller Be

The company sans CEO Scangos needs to do some type of deal in the coming months.

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Relypsa Finally Finds Buyer, but Potential Seen For Rival Bid

Relypsa Finally Finds Buyer, but Potential Seen For Rival Bid

Shares of Relypsa are rallying after the company announced it has agreed to be acquired by Galenica Group in a $1.53B deal.

Sanofi (SNY) Moving On Heavy Volume In The Pre-Market Hours

Sanofi (SNY) Moving On Heavy Volume In The Pre-Market Hours

Trade-Ideas LLC identified Sanofi (SNY) as a pre-market mover with heavy volume candidate

Sanofi (SNY) Flagged As A Storm The Castle Stock

Sanofi (SNY) Flagged As A Storm The Castle Stock

Trade-Ideas LLC identified Sanofi (SNY) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate

Award-Winning Chef Elizabeth Falkner Reveals Her Struggle With Atopic Dermatitis To Highlight The Physical And Psychological Impact Of The Disease

Award-Winning Chef Elizabeth Falkner Reveals Her Struggle With Atopic Dermatitis To Highlight The Physical And Psychological Impact Of The Disease

Falkner has joined forces with Regeneron and Sanofi Genzyme in collaboration with leading dermatology organizations to educate Americans about a potentially serious, chronic inflammatory skin disease known as atopic dermatitis.